History of Changes for Study: NCT03893240

Neutralizing Antibody Screening Study With a Retrospective Component in Participants With Late-Onset Pompe Disease

Latest version (submitted March 23, 2023) on ClinicalTrials.gov

A study version is represented by a row in the table.
Select two study versions to compare. One each from columns A and B.
Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
Click "Compare" to do the comparison and show the differences.
Select a version's Submitted Date link to see a rendering of the study for that version.
The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
Hover over the "Recruitment Status" to see how the study's recruitment status changed.
Study edits or deletions are displayed in red.
Study additions are displayed in green.

Study Record Versions

Version	Submitted Date	Changes
1	March 26, 2019	None (earliest Version on record)
2	July 19, 2019	Recruitment Status, Study Status, Contacts/Locations and Study Identification
3	September 9, 2019	Contacts/Locations, Study Status and Eligibility
4	December 3, 2019	Study Status and Contacts/Locations
5	May 14, 2020	Recruitment Status, Study Status and Contacts/Locations
6	August 25, 2020	Recruitment Status, Study Status, Contacts/Locations, Outcome Measures, Arms and Interventions and Study Description
7	July 14, 2021	Recruitment Status, Study Status, Contacts/Locations and Study Design
8	March 23, 2023	Study Status

Comparison Format:

Merged
Side-by-Side

Scroll up to access the controls

Study NCT03893240
Submitted Date: March 26, 2019 (v1)

Study Identification


Unique Protocol ID:	SPK-GAA-100
Brief Title:	Neutralizing Antibody Screening Study With a Retrospective Component in Participants With Late-Onset Pompe Disease
Official Title:	A Multi-Center, Low-Interventional Study With a Retrospective Component in Participants With Late-Onset Pompe Disease
Secondary IDs:

Study Status


Record Verification:	March 2019
Overall Status:	Not yet recruiting
Study Start:	April 2019
Primary Completion:	February 2022 [Anticipated]
Study Completion:	February 2022 [Anticipated]

First Submitted:	March 11, 2019
First Submitted that Met QC Criteria:	March 26, 2019
First Posted:	March 28, 2019 [Actual]

Last Update Submitted that Met QC Criteria:	March 26, 2019
Last Update Posted:	March 28, 2019 [Actual]

Study Description

Brief Summary:

The purpose of this study is to obtain information pertaining to the occurrence of antibodies to investigational SPK-3006 and GAA, GAA activity and GAA antigen levels in the usual care setting of Late-Onset Pompe Disease (LOPD) participants on an enzyme replacement regimen. Additionally, a careful evaluation of laboratory and functional testing in patients with LOPD may provide information to better understand the disease features and better drive the design of a future interventional investigational gene therapy trial. An understanding of the underlying status of liver and muscle health in individuals with LOPD may also inform best surveillance during the conduct of gene therapy trials.

Detailed Description:

Conditions


Conditions:	Pompe Disease Pompe Disease (Late-onset) Glycogen Storage Disease Type 2 LOPD Lysosomal Storage Diseases Acid Maltase Deficiency
Keywords:

Study Design


Study Type:	Interventional
Primary Purpose:	Screening
Study Phase:	Not Applicable
Interventional Study Model:	Single Group Assignment
Number of Arms:	1
Masking:	None (Open Label)
Allocation:	N/A
Enrollment:	60 [Anticipated]

Arms and Interventions

Arms

Assigned Interventions

Participants with Late Onset Pompe disease

This is a multi-center, low-interventional study with a retrospective component in participants with LOPD. During a single study visit, assessments including but not limited to, liver health, neutralizing antibodies to SPK-3006 capsid and GAA, anti-GAA binding antibodies, GAA activity and GAA antigen levels will be performed. Additional information will be collected to provide retrospective evaluations relating to muscle and liver inflammation and/or injury. Historic data relating to Pompe disease will be collected from medical records. The retrospective and laboratory data collected may assist in providing baseline information for a future investigational gene therapy study.

Diagnostic Test: SPK-3006 Neutralizing Antibody

Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.

Outcome Measures


Primary Outcome Measures:
1.	SPK-3006 Neutralizing Antibodies Titer [ Time Frame: 1 day ] The SPK-3006 neutralizing antibodies titer is measured once prospectively at one site visit.
2.	Occurrence of SPK-3006 Neutralizing Antibodies [ Time Frame: 1 day ] The proportion of participants who have Neutralizing Antibodies to SPK-3006.
Secondary Outcome Measures:
1.	Anti-GAA binding antibodies Titer [ Time Frame: 1 day ] Anti-GAA binding antibodies titer is measured once prospectively at one site visit.
2.	Occurrence of Anti-GAA binding antibodies across participants [ Time Frame: 1 day ] The proportion of participants who have Anti-GAA binding antibodies.
3.	Neutralizing antibodies to circulating GAA Titer [ Time Frame: 1 day ] Neutralizing antibodies to circulating GAA titer is measured once prospectively at one site visit and, if available, retrospectively from medical records that are within 24 months of signing the informed consent.
4.	Occurrence of Neutralizing antibodies to circulating GAA [ Time Frame: 1 day ] The proportion of participants who have neutralizing antibodies to circulating GAA.
5.	GAA activity level [ Time Frame: 1 day ] GAA activity level (percent of normal) is measured once prospectively at one site visit and, if available, retrospectively from medical records that are within 24 months of signing the informed consent.
6.	GAA antigen level [ Time Frame: 1 day ] GAA antigen level (percent of normal) is measured once prospectively at one site visit and, if available, retrospectively from medical records that are within 24 months of signing the informed consent.

Eligibility


Minimum Age:	18 Years
Maximum Age:
Sex:	All
Gender Based:
Accepts Healthy Volunteers:	No
Criteria:	Inclusion Criteria: Provide written informed consent and authorization to use protected health information in accordance with national and local privacy regulations Male or females ≥18 years of age Currently on ERT using regular recombinant human GAA infusions for at least 18 months prior to screening Documented history of clinically moderate late-onset Pompe disease. Exclusion Criteria: History of HIV infection Requires any invasive ventilation (other than BiPAP at night) or noninvasive ventilation while awake and upright Previously received SPK-3006 Previously dosed with any investigational or approved gene therapy product at any time or treated with an investigational drug within the last 12 weeks (vaccination studies are accepted) Any concurrent clinically significant condition that would not allow the potential participant to complete the Day 1 examinations, or other condition that, in the opinion of the Investigator and/or Sponsor, makes the subject unsuitable for participation in the study Unable or unwilling to comply with the schedule of visits and/or study assessments described in the clinical protocol.

Contacts/Locations


Central Contact Person:	Clinical Director Telephone: +1 215-220-9300 Email: clinicaltrials@sparktx.com
Central Contact Backup:	Clinical Director Email: clinicaltrials@sparktx.com
Locations:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services